Publicacións nas que colabora con Tomas Sobrino Moreiras (142)

2024

  1. Correction to: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial (Nature Communications, (2024), 15, 1, (5251), 10.1038/s41467-024-49121-3)

    Nature Communications

  2. Correction to: dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe (Nature Communications, (2024), 15, 1, (3736), 10.1038/s41467-024-47751-1)

    Nature Communications

  3. Differential blood-based biomarkers of subcortical and deep brain small vessel disease

    Therapeutic Advances in Neurological Disorders, Vol. 17

  4. Partial volume correction in longitudinal tau PET studies: is it really needed?

    NeuroImage, Vol. 289

  5. Precision Medicine for Blood Glutamate Grabbing in Ischemic Stroke

    International Journal of Molecular Sciences, Vol. 25, Núm. 12

  6. Preclinical validation of human recombinant glutamate-oxaloacetate transaminase for the treatment of acute ischemic stroke

    iScience, Vol. 27, Núm. 11

  7. Quantitative brain [18F]FDG PET beyond normal blood glucose levels

    NeuroImage, Vol. 300

  8. Systemic biomarker associated with poor outcome after futile reperfusion

    European Journal of Clinical Investigation, Vol. 54, Núm. 6

  9. The systemic impact of non-surgical treatment of peri-implantitis with or without adjunctive systemic metronidazole: Secondary analysis of a randomized clinical trial

    Clinical Oral Implants Research

  10. dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe

    Nature Communications, Vol. 15, Núm. 1